Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lisocabtagene maraleucel (Liso-cel) versus standard of care in adults with relapsed or refractory follicular lymphoma has been withdr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Liso-cel (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Relapsed or Refractory Follicular Lymphoma | Phase 3 | Status: WITHDRAWN